HC Wainwright Analysts Lower Earnings Estimates for CTMX

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for CytomX Therapeutics in a note issued to investors on Monday, March 16th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings per share of ($0.14) for the quarter, down from their prior forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.65) EPS.

A number of other equities research analysts have also weighed in on CTMX. Piper Sandler boosted their price target on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Oppenheimer reiterated an “outperform” rating and issued a $12.00 target price on shares of CytomX Therapeutics in a research note on Monday. Cantor Fitzgerald boosted their target price on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Wedbush upped their price target on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Barclays raised their price target on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

CytomX Therapeutics Trading Down 19.3%

Shares of NASDAQ CTMX opened at $5.45 on Wednesday. The stock’s fifty day simple moving average is $5.26 and its two-hundred day simple moving average is $4.09. CytomX Therapeutics has a 12-month low of $0.40 and a 12-month high of $8.21. The stock has a market capitalization of $923.39 million, a PE ratio of -136.25 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 20.65%. The company had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $7.33 million.

Institutional Investors Weigh In On CytomX Therapeutics

Hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC purchased a new position in shares of CytomX Therapeutics in the 3rd quarter valued at about $25,000. Wells Fargo & Company MN raised its position in shares of CytomX Therapeutics by 83.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares during the last quarter. Invesco Ltd. acquired a new stake in shares of CytomX Therapeutics in the second quarter valued at about $32,000. Pursue Wealth Partners LLC purchased a new position in CytomX Therapeutics in the 2nd quarter worth approximately $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in CytomX Therapeutics during the third quarter worth about $34,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Key CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase I Varseta‑M data show stronger-than-expected responses (e.g., ~32% response at the higher dose and ~7.1 months estimated PFS), which sparked a major rally and underpins the stock’s recent upside. Zacks: CTMX Stock Rallies
• Positive Sentiment: Multiple broker actions followed the clinical readout — JPMorgan upgraded CTMX to overweight (new $12 PT) and other firms (Wedbush, HC Wainwright) raised price targets (HC Wainwright to $17) or issued Buy/outperform opinions, adding momentum. Seeking Alpha: Upgrade Coverage
• Neutral Sentiment: Company posted Q4 results and released the earnings slide deck/transcript; these materials reiterate clinical progress but showed weak near-term revenue — useful for modeling but not a catalyst by themselves. Q4 Slide Deck
• Negative Sentiment: CytomX priced a $250M underwritten public offering (45.99M shares at $5.30 and pre‑funded warrants), which is dilutive and typically puts near‑term pressure on the share price. Closing expected March 19, subject to conditions. GlobeNewswire: Offering Priced
• Negative Sentiment: Q4 results missed expectations: EPS ($0.22) vs. consensus ($0.08) loss and revenue of $0.66M well below estimates, highlighting current financial drag. Zacks: Q4 Miss
• Negative Sentiment: HC Wainwright trimmed near‑term and FY2026 EPS forecasts (Q1–Q4 and FY26/FY27 EPS lowered), signaling expectations for higher cash burn or slower commercial/partner revenue in the near term despite keeping a Buy rating. MarketBeat: Analyst Estimate Changes

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.